Loading…
Loading…
Dave Ramsey and Suze Orman have built careers on helping people retire with dignity, yet on one of the most consequential investment decisions a retiree faces, they point in completely opposite directions. For a nest egg of $107,000, that disagreement is not academic.
J&J's MedTech faces Abiomed and competitive pressures, but Vision, Orthopedics and Surgery could drive a stronger second half.
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Johnson & Johnson (JNJ). But which of these two stocks offers value investors a better bang for their buck right now?
Yield alone tells you nothing about whether a dividend actually survives a recession or a patent cliff.
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Both Dividend Kings trade at nearly identical valuations, so the real question becomes which one can actually keep raising its payout for two decades without flinching. The answer comes down to three factors most investors overlook entirely.
Johnson & Johnson (JNJ) closed at $252.83 in the latest trading session, marking a -1.25% move from the prior day.
Rockland Trust Co. reduced its position in Johnson and Johnson (NYSE: JNJ) by 5.3% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 74,352 shares of the company's stock after selling 4,125 shares during the period. Rockland Trust